Scarica l'app Stockscreener
1.47
3.31%
-0.0503
Precedente Chiudi:
$1.5203
Aprire:
$1.51
Volume 24 ore:
48,403
Relative Volume:
0.16
Capitalizzazione di mercato:
$105.97M
Reddito:
$5.15M
Utile/perdita netta:
$-65.35M
Rapporto P/E:
-1.0889
EPS:
-1.35
Flusso di cassa netto:
$-20.85M
1 W Prestazione:
-6.96%
1M Prestazione:
+0.68%
6M Prestazione:
-21.39%
1 anno Prestazione:
-49.31%
Intervallo 1D:
$1.47
$1.60
Intervallo di 1 settimana:
$1.4602
$1.60
Portata 52W:
$1.10
$2.9126
Cellectis Adr Stock (CLLS) Company Profile
Confronta CLLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
1.47 | 158.46M | 5.15M | -65.35M | -20.85M | -1.35 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2022-05-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Robert W. Baird | Outperform |
| 2020-03-06 | Downgrade | Goldman | Neutral → Sell |
| 2019-10-30 | Ripresa | Guggenheim | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-05-24 | Ripresa | Citigroup | Neutral |
| 2019-03-14 | Iniziato | William Blair | Outperform |
| 2018-12-19 | Iniziato | Goldman | Neutral |
| 2018-07-16 | Iniziato | Barclays | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2017-09-05 | Downgrade | SunTrust | Buy → Hold |
| 2017-09-05 | Reiterato | Wells Fargo | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-02-28 | Iniziato | Wells Fargo | Outperform |
| 2016-04-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-02 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Iniziato | BofA/Merrill | Buy |
| 2015-04-20 | Iniziato | Jefferies | Buy |
| 2015-04-20 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Cellectis Adr Borsa (CLLS) Ultime notizie
Cellectis S.A. announces board change and meeting By Investing.com - Investing.com India
Cellectis S.A. announces board change and meeting - Investing.com
European Equities See Growth In US Trade - Finimize
Cellectis earnings beat by $0.06, revenue topped estimates - Investing.com India
Cellectis earnings beat by $0.07, revenue topped estimates - Investing.com
Cellectis Charts Course For 2025 With Boost From AstraZeneca Deal - Barchart.com
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Cellectis stock touches 52-week low at $1.14 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
Cellectis’s SWOT analysis: biotech firm’s stock faces CAR T challenges - Investing.com
Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% By Investing.com - Investing.com South Africa
Cellectis stock touches 52-week low at $1.2 amid market challenges - Investing.com India
Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% - Investing.com India
What Recent Market Trends Mean for Cosan S.A ADR’s (CSAN) Stock - The News Heater
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Cellectis stock touches 52-week low at $1.24 amid market challenges - Investing.com India
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS) - MarketBeat
Cellectis earnings missed by $0.20, revenue fell short of estimates - Investing.com
Cellectis stock touches 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Cellectis stock touches 52-week low at $1.4 amid market challenges - Investing.com India
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
This Penny Stock Has 270% Upside Potential In 2025. Is It A Buy Now? - Barchart
Analysts Predict 400% Upside Potential for This Penny Stock - Yahoo Finance
Cellectis stock plunges to 52-week low at $1.52 amid market challenges - Investing.com India
Cellectis stock touches 52-week low at $1.7 amid market challenges - Investing.com
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year - Investing.com India
Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year ahead - Investing.com
Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
AstraZeneca completes equity investment agreement with Cellectis - AstraZeneca
CellectisADR (CLLS) Price Target Increased by 7.35% to 11.62 - Nasdaq
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature
Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis - Investor's Business Daily
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U
7 Gene Editing Companies Investors Should Watch - Nanalyze
AZN Stock Price and Chart — LSE:AZN - TradingView
Cellectis Adr Azioni (CLLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):